Evidence map›Paper›PMID 40356719›Full record

ArticleFrontiers in molecular biosciences2025

MRI-based deep learning with clinical and imaging features to differentiate medulloblastoma and ependymoma in children.

Yasen Yimit, Parhat Yasin, Yue Hao, Abudouresuli Tuersun, Chencui Huang, Xiaoguang Zou, Ya Qiu, Yunling Wang, Mayidili Nijiati

Abstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The role of machine learning, deep learning, and MRI findings in the classification of pediatric posterior fossa tumors.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yasen Yimit *Department of Radiology, The First People's Hospital of Kashi Prefecture, Kashgar, China.
Parhat Yasin *The Sixth Affiliated Hospital of Xinjiang Medical University Department of Spine Surgery, Urumqi, China.
Yue Hao *Department of Radiology, The First People's Hospital of Kashi Prefecture, Kashgar, China.
Abudouresuli TuersunDepartment of Radiology, The First People's Hospital of Kashi Prefecture, Kashgar, China.
Chencui HuangDepartment of Research Collaboration, R&D Center, Beijing Deepwise and League of PHD Technology Co., Ltd., Beijing, China.
Xiaoguang ZouThe Xinjiang Key Laboratory of Artificial Intelligence Assisted Imaging Diagnosis, Varanasi, China.
Ya QiuDepartment of Radiology, The First People's Hospital of Kashi Prefecture, Kashgar, China.
Yunling WangFirst Affiliated Hospital of Xinjiang Medical University Department of Imaging Center, Urumqi, China.
Mayidili NijiatiThe Xinjiang Key Laboratory of Artificial Intelligence Assisted Imaging Diagnosis, Varanasi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Medulloblastoma (MB) and ependymoma (EM) in children share similarities in terms of age group, tumor location, and clinical presentation, which makes it challenging to clinically diagnose and distinguish them. Purpose: The present study aims to explore the effectiveness of T2-weighted magnetic resonance imaging (MRI)-based deep learning (DL) combined with clinical imaging features for differentiating MB from EM. Methods: Axial T2-weighted MRI sequences obtained from 201 patients across three study centers were used for model training and testing. The regions of interest were manually delineated by an experienced neuroradiologist with supervision by a senior radiologist. We developed a DL classifier using a pretrained AlexNet architecture that was fine-tuned on our dataset. To mitigate class imbalance, we implemented data augmentation and employed K-fold cross-validation to enhance model generalizability. For patient classification, we used two voting strategies: hard voting strategy in which the majority prediction was selected from individual image slices; soft voting strategy in which the prediction scores were averaged across slices with a threshold of 0.5. Additionally, a multimodality fusion model was constructed by integrating the DL classifier with clinical and imaging features. The model performance was assessed using a 7:3 random split of the dataset for training and validation, respectively. The key metrics like sensitivity, specificity, positive predictive value, negative predictive value, F1 score, area under the receiver operating characteristic curve (AUC), and accuracy were calculated, and statistical comparisons were performed using the DeLong test. Thereafter, MB was classified as positive, while EM was classified as negative. Results: The DL model with the hard voting strategy achieved AUC values of 0.712 (95% confidence interval (CI): 0.625-0.797) on the training set and 0.689 (95% CI: 0.554-0.826) on the test set. In contrast, the multimodality fusion model demonstrated superior performance with AUC values of 0.987 (95% CI: 0.974-0.996) on the training set and 0.889 (95% CI: 0.803-0.949) on the test set. The DeLong test indicated a statistically significant improvement in AUC values for the fusion model compared to the DL model ( Conclusion: T2-weighted MRI-based DL combined with multimodal clinical and imaging features can be used to effectively differentiate MB from EM in children. Thus, the structure of the decision tree in the decision tree classifier is expected to greatly assist clinicians in daily practice.

Indexed as

deep learningependymomamagnetic resonance imagingmedulloblastomaT2-weighted imaging

Identifiers

PMID40356719
PMCPMC12066621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.